Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Cerilliant
Federal Trade Commission
US Army
Citi
Chinese Patent Office
US Department of Justice
Teva
Daiichi Sankyo
Colorcon

Generated: August 16, 2017

DrugPatentWatch Database Preview

PAZEO Drug Profile

« Back to Dashboard

Which patents cover Pazeo, and when can generic versions of Pazeo launch?

Pazeo is a drug marketed by Novartis Pharms Corp and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-five patent family members in seventeen countries.

The generic ingredient in PAZEO is olopatadine hydrochloride. There are seventeen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the olopatadine hydrochloride profile page.

Summary for Tradename: PAZEO

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list27
Patent Applications: see list1,715
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:PAZEO at DailyMed

Pharmacology for Tradename: PAZEO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp
PAZEO
olopatadine hydrochloride
SOLUTION/DROPS;OPHTHALMIC206276-001Jan 30, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Novartis Pharms Corp
PAZEO
olopatadine hydrochloride
SOLUTION/DROPS;OPHTHALMIC206276-001Jan 30, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
PAZEO
olopatadine hydrochloride
SOLUTION/DROPS;OPHTHALMIC206276-001Jan 30, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Novartis Pharms Corp
PAZEO
olopatadine hydrochloride
SOLUTION/DROPS;OPHTHALMIC206276-001Jan 30, 2015RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: PAZEO

Drugname Dosage Strength RLD Submissiondate
olopatadine hydrochlorideOphthalmic Solution0.7%Pazeo9/10/2015

International Patent Family for Tradename: PAZEO

Country Document Number Estimated Expiration
Uruguay34074► Subscribe
Mexico2013010039► Subscribe
World Intellectual Property Organization (WIPO)2012159064► Subscribe
Japan2014515355► Subscribe
Russian Federation2013140423► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: PAZEO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0040France► SubscribePRODUCT NAME: OLOPATADINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/02/217/001 20020517
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
AstraZeneca
QuintilesIMS
Merck
Citi
Baxter
Cipla
Accenture
Teva
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot